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Background: This study assesses the relationships between lymphocyte and monocyte subsets and intelligence
quotient (IQ) scores in antiretroviral therapy (ART)-naive, HIV-infected Thai children without advanced HIV disease.
Findings: Sixty-seven ART-naive Thai children with CD4 between 15-24% underwent cognitive testing by Weschler
intelligence scale and had 13 cell subsets performed by flow cytometry including naive, memory and activated
subsets of CD4+ and CD8+ T cells, activated and perivascular monocytes and B cells. Regression modelling with
log10 cell count and cell percentage transformation was performed.
Median age (IQR) was 9 (7–10) years, 33% were male, CDC stages N:A:B were 1:67:31%, median CD4% and count
(IQR) were 21 (18–24)%, 597 (424–801) cells/mm3 and HIV RNA (IQR) was 4.6 (4.1-4.9) log10 copies/ml. Most (82%)
lived at home, 45% had a biological parent as their primary caregiver, and 26 (49%) had low family income. The
mean (SD) scores were 75 (13) for full scale IQ (FIQ), 73 (12) for verbal IQ (VIQ) and 80 (14) for performance IQ (PIQ).
Adjusted multivariate regression analysis showed significant negative associations between B cell counts and FIQ,
VIQ and PIQ (p < 0.01 for all); similar associations were found for B cell percentages (p < 0.05 for all).
Conclusions: High B cell counts and percentages were strongly associated with poorer FIQ, VIQ and PIQ scores.
Prospective, long-term assessment of cell subsets and determination of relevant B cell subpopulations could help
further elucidate associations between lymphocyte subsets and neurocognitive development.
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Introduction
HIV causes neurocognitive impairment possibly by trans-
migration through the blood brain barrier of activated T
cells and infected monocytes triggering a cascade of in-
flammatory processes [1]. HIV encephalopathy, a severe
form of neurocognitive impairment in children, has be-
come less common since antiretroviral therapy (ART) be-
came widely available. However, chronic stable cognitive
and behavioral deficits remain, predicting academic im-
pairments in school [2]. Limited studies in US children* Correspondence: jintanat.a@hivnat.org
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article, unless otherwise stated.have suggested that certain lymphocyte subsets may
predict poorer cognition [3,4]. Here we assess the rela-
tionships between lymphocyte and monocyte subsets
and intelligence quotient (IQ) scores in ART-naive, HIV-
infected Thai children without advanced HIV disease.Materials and methods
We utilized data from the baseline visit of a 3-year PRE-
DICT immediate vs. deferred ART study (http://www.
clinicaltrials.gov/ct/show/NCT00234091) which enrolled
ART-naïve children aged 1 to 12 years with CD4 15-24%
and no AIDS illnesses. The data included in this analysis
were from Thai children at 7 clinical sites who had both
flow cytometry and cognitive testing performed before the
initiation of ART. The flow cytometry was done according
to Pediatric AIDS Clinical Trials Group procedures atCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Socio-demographic and disease-related
characteristics of children in the study
Characteristic N (%) or Median (IQR)
Age 9 (7 – 10) years
Proportion of females 45 (67%)
Thai ethnicity 67 (100%)
Height for age z-score −1.28 (−1.88, -0.68)
Weight for age z-score −1.1 (−1.66, -0.57)





CD4 percent 21 (18 – 24)%
Log10 plasma HIV-RNA (copies/mL) 4.6 (4.1 – 4.9)
Transmission route
Perinatal infection 67 (100%)
Exposure to nevirapine for PMTCT 6 (9%)
Income
Very low 8 (11.9)
Low 18 (26.9)
Average 25 (37.3)







Step father/mother or foster mother 3 (4.5)
Others 2 (3.0)





PMTCT prevention of mother to child transmission.
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certified laboratories with rigorous quality assurance
programs [5]. The 13 cell subsets included CD45+/3+/19-
(Total T cells), CD45+/3+/4+ (Helper T cells), CD4+/45RA+/
62 L + (Naive helper T cells), CD3+/4+/45RO + (Memory
helper T cells), CD4+/DR+/38+ (Activated helper T cells),
CD45+/3+/8+ (Cytotoxic T cells), CD8+/45RA+/62 L +
(Naive cytotoxic T cells), CD3+/4-/45RO+ (Memory cyto-
toxic T cells), CD8+/DR+/38+ (Activated cytotoxic T cells),
CD45+/3-/19+ (B cells), CD45+/3-/16+/56+ (Natural killer
cells or NK cells), CD14+/16+/DR + (Activated monocytes)
and CD14+/16+/163+ (Perivascular monocytes believed to
be precursors of brain perivascular macrophages) [6]. Cog-
nitive functioning was assessed with Wechsler Preschool
and Primary Scale of Intelligence II for those between 2.5
and 6 years or Wechsler Intelligence Scale for Children III
for children ≥ 6 years of age. Quality assurance was per-
formed by a US neuropsychologist.
Children’s characteristics were described by median,
interquartile range (IQR) or percentages, as appropriate.
Each cell subset percentage and count was used as a
continuous covariate. Regression modelling with both
log10 transformed cell count and cell percentage as out-
come variables was performed against IQ scores, and ad-
justment was made for age, gender, HIV RNA, education
of caregiver and socioeconomic status. Analyses were
performed with Stata 12.1 (Statacorp, College Station,
Tx, USA). The level of significance was based on P value
of less than 0.05.
The study was approved by the following institu-
tional review boards in Thailand: the Ministry of Public
Health, Chulalongkorn University, Khon Kaen University,
Bamrasnaradura Infectious Disease Institute, Chiangrai
Prachanukroh Hospital and Queen Savang Vadhana
Memorial Hospital.
Results
A total of 67 ART-naive Thai children were included in
the analysis, and characteristics are summarized in Table 1.
Their median age (IQR) was 9 (7–10) years, 33% were
male, Center for Disease Control and Prevention stages N:
A:B were 2:67:31%, median CD4% and count (IQR) were
21 (18–24)% and 597(424–801) cells/mm3, and median
HIV RNA (IQR) was 4.6 (4.1-4.9) log10 copies/ml. Most
(82%) lived at home, with 45% having a biological parent
as their primary caregiver. Twenty-two (33%) had care-
givers who had education equal to high school/bachelor,
and 26 (39%) had low or very low family income. Median
time (IQR) between IQ test and cell subsets was 3 (1–5)
months.
The mean (SD) scores were 75 (13) for full scale IQ
(FIQ), 73 (12) for verbal IQ (VIQ) and 80 (14) for per-
formance IQ (PIQ). The median (IQR) scores of each cell
subset percentages and counts are included in Table 2.Multivariate regression analysis was performed to
evaluate associations between cell subsets and IQ scores
(Table 2). After adjusting for age, gender, HIV RNA,
education of caregiver and income, significant negative
associations between B cell counts with FIQ, VIQ and
PIQ were observed (p < 0.01 for all). Similar negative asso-
ciations were found for B cell percentages (p < 0.01 for
FIQ and PIQ; p < 0.05 for VIQ). There was a marginal in-
verse association between memory cytotoxic T cell count
and VIQ (p = 0.048). The other cell subsets showed no sig-
nificant associations with IQ scores.
Table 2 Multivariate regression analysis of associations between cell subsets and intelligent quotients
Multivariate regression analysis
Coefficient (95% CI), p value
Cellsubsets Median (IQR) Full-scale IQ Verbal IQ Performance IQ
Cell counts
Total T 2079 (1547,2666) −9.8 (−42.8, 23.2), p 0.55 −10.1 (−37.7, 17.6), p 0.46 −10.0 (−46.0, 26.0), p 0.57
B 321 (247,481) −40.0 (−63.8, -16.2), p 0.002 −31.7 (−52.2, -11.3), p 0.004 −37.1 (−62.4, -11.9), p 0.005
Natural killer 297 (152,386) 7.0 (−8.9, 22.8), p 0.38 3.3 (−10.1, 16.7), p 0.62 8.5 (−8.7, 25.6), p 0.32
Helper T 594 (362,795) −8.5 (−34.7, 17.6), p 0.51 −8.4 (−30.3, 13.5), p 0.44 −8.4 (−36.6, 19.9), p 0.55
Cytotoxic T 1360 (970,1697) −3.4 (−36.6, 29.8), p 0.84 −6.7 (−34.5, 21.1), p 0.62 −2.1 (−38.4, 34.3), p 0.91
Naïve helper T 314 (168,417) −6.5 (−21.5, 8.6), p 0.39 −6.4 (−18.9, 6.2), p 0.31 −5.8 (−22.2, 10.6), p 0.47
Naïve cytotoxic T 311 (240,451) −5.7 (−27.3, 15.8), p 0.59 −3.4 (−21.5, 14.8), p 0.70 −6.9 (−30.6, 16.8), p 0.55
Activated helper T 67 (39,98) 4.4 (−16.5, 25.3), p 0.67 2.9 (−14.7, 20.4), p 0.74 1.9 (−20.0, 23.8), p 0.86
Activated cytotoxic T 584 (460,865) −7.7 (−38.1, 22.7), p 0.61 −6.6 (−32.2, 18.9), p 0.60 −11.1 (−43.4, 21.2), p 0.49
Memory helper T 228 (168,305) −2.2 (−30.8, 26.5), p 0.88 −7.0 (−31.0, 16.9), p 0.55 0.7 (−29.4, 30.7), p 0.96
Memory cytotoxic T 683 (543,908) −27.2 (−57.5, 3.0), p 0.08 −25.3 (−50.4, -0.3), p 0.048 −26.0 (−58.3, 6.3), p 0.11
Activated monocytes 58 (33,115) 17.4 (−3.3, 38.1), p 0.10 11.3 (−6.1, 28.7), p 0.19 15.9 (−7.2, 38.9), p 0.17
Perivascular monocytes 31 (12,59) −4.2 (−15.4, 6.9), p 0.44 −2.9 (−12.1, 6.3), p 0.52 −6.3 (−18.0, 5.4), p 0.28
Cell percentages
CD4/CD8 0.4 (0.4,0.5) −17.4 (−60.5, 25.6), p 0.41 −11.3 (−47.7, 25.1), p 0.53 −19.7 (−66.6, 27.2), p 0.40
Total T 76.1 (69.5.80.3) 11.1 (−121.0, 143.2), p 0.86 10.2 (−100.8, 121.2), p 0.85 8.0 (−131.3, 147.2), p 0.91
B 12.4 (9.3.15.9) −43.5 (−71.8, -15.1), p 0.004 −32.2 (−56.9, -7.5), p 0.012 −45.5 (−76.5, -14.5), p 0.005
Natural killer 8.5 (5.8,12.3) 11.9 (−5.6, 29.5), p 0.17 7.4 (−7.5, 22.4), p 0.32 14.3 (−5.0, 33.5), p 0.14
Helper T 20.6 (16.1,22.9) −8.6 (−64.0, 46.8), p 0.75 −7.3 (−53.8, 39.3), p 0.75 −8.7 (−69.9, 52.6), p 0.77
Cytotoxic T 50.3 (44.5,54) 37.4 (−37.8, 112.5), p 0.32 21.0 (−42.7, 84.7), p 0.51 43.4 (−37.0, 123.8), p 0.28
Naïve helper T 49.5 (42,60.2) −12.2 (−39.8, 15.4), p 0.37 −12.1 (−35.2, 10.9), p 0.29 −10.4 (−40.8, 20.1), p 0.49
Naïve cytotoxic T 24.1 (18.2,29.4) −9.9 (−42.5, 22.8), p 0.54 −1.2 (−28.9, 26.4), p 0.93 −12.9 (−47.5, 21.6), p 0.45
Activated helper T 10.9 (8.7-15.4) 8.0 (−10.7, 26.7), p 0.39 6.7 (−9.0, 22.4), p 0.39 6.2 (−14.4, 26.8), p 0.54
Activated cytotoxic T 49.7 (39,59.6) −10.2 (−54.3, 34.0), p 0.64 −2.0 (−39.2, 35.2), p 0.91 −20.6 (−68.0, 26.7), p 0.38
Memory helper T 10.9 (9.9,13.3) 8.0 (−27.5, 43.4), p 0.65 0.7 (−29.1, 30.6), p 0.96 12.4 (−25.6, 50.4), p 0.51
Memory cytotoxic T 34.2 (29.9,41.4) −26.2 (−63.3, 10.8), p 0.16 −23.2 (−54.2, 7.9), p 0.14 −26.6 (−67.3, 14.0), p 0.19
Activated monocytes 11.1 (8.1,16.7) 22.0 (−3.9, 47.9), p 0.09 18.0 (−3.3, 39.4), p 0.09 18.1 (−11.1, 47.3), p 0.21
Perivascular monocytes 6.5 (2.1,10.1) −6.7 (−19.4, 6.1), p 0.29 −3.8 (−14.4, 6.9), p 0.47 −9.5 (−22.8, 3.8), p 0.15
Regression analysis was performed with an outcome variable of log10 transformed T cell subset percentages and counts, versus cognitive outcomes adjusted for
potential confounders (age, gender, HIV RNA, education of primary caregiver and household income).
IQ Intelligence quotient.
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The present study evaluated the associations between 13
peripheral blood mononuclear cell subsets and IQ scores
in ART-naive, HIV-infected Thai children with mild to
moderate immune suppression. Higher B cell percentages
and counts were strongly associated with poorer FIQ, VIQ
and PIQ.
B-cell perturbation in particular over proliferation of
aberrant B cell populations and immunoglobulins, and
depletion of resting memory B cells, is a marker for HIV-
associated immune deficiency. Such aberrations are linked
to high HIV viremia and low CD4 nadir [7]. Although nopublished report exists on the association of B cells with
neurodevelopment in HIV-infected children, higher B cell
counts have been reported in children with autism and
postulated to contribute to autoimmune response and
neurodevelopment disorder in that disease [8]. B lympho-
cytes can enter the brain and they tend to display an
activated phenotype. In HIV-infected patients, increased
numbers of B cells in autopsied brain parenchyma and
perivascular spaces are observed [9]; possibly playing a
role in brain inflammation and insult leading to poorer
neurocognition. The marginal significant association be-
tween higher memory CD8+ T cell counts with poorer
Ananworanich et al. AIDS Research and Therapy 2014, 11:7 Page 4 of 5
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HIV disease. Persistent exposure to HIV viremia can lead
to preferential depletion of naive CD8+ T cells and skewed
maturation of memory CD8+ T cells [10].
We did not observe a negative association between acti-
vated cytotoxic T cells and neurocognition as reported in
a US study by Mekmullica et al. In that study, the relative
absence of activated cytotoxic T cells, CD8 +HLA-DR +
and CD8 + 38+ cells, in the first few months of life was
strongly associated with favorable psychomotor outcomes
in the first 2 years of life [3]. Activated cytotoxic T cells
could migrate into the brain and cause production of pro-
inflammatory cytokines and neurotoxins resulting in
neuronal dysfunction [1]. However, Kapetanovic S, et al.
recently reported higher activated cytotoxic T cell percent-
age, using the same surface markers, to have a neuropro-
tective effect in a group of older ART-treated, US children
with advanced HIV disease [4]. The discrepancies in asso-
ciations between T cell subsets and neurocognition in
these two latter studies and our own study might partially
be accounted for by differences in study population in age
and HIV disease severity. Children in the Mekmullica
study were newborn at the time of lymphocyte collection,
whereas those in the study by Kapetanovic ranged from 1
year to teenagers, and were mostly heavily pretreated with
advanced HIV disease. In contrast, our study was con-
ducted in children with less advanced disease than those
described by Kapetanovic. Although the Mekmullica study
states that B cells were enumerated, the results were not
included in the paper which might suggest that no signifi-
cant association was found, but nevertheless precludes
direct comparison with the results in our study.
It must be acknowledged that the peripheral blood B
cell compartment contains several distinct B cell types,
e.g., immature/transitional (CD10+, CD27-, activated/
mature (CD21lo CD10-), and resting memory (CD21hi
CD27+) [11]. None of these subsets were included in the
measurements in this report and further studies will be
necessary to determine the neurotoxic B cell subpopula-
tion. The presence of activated monocytes has also been
associated with neurocognitive impairment but we did
not see this in our study. CD163 is a scavenger receptor
expressed on monocytes and macrophages that are thought
to be precursors of perivascular macrophages that traffic
to the brain [6,12]. They are seen in higher frequencies in
HIV-infected subjects compared to healthy controls, and
increased frequencies are associated with HIV viremia and
low CD4 count [12]. Therefore the weak negative associ-
ation between these perivascular monocytes and PIQ may
be due to untreated HIV disease.
Our study is limited by the small number of children.
As previously noted, they were relatively well without ad-
vanced HIV disease and were not yet treated with ART.
Age, ethnicity and environment can affect both cell subsetdistribution and neurocognition [2,5]. These factors may
limit the generalizability of our data to other populations.
We did not have data from age-matched HIV negative
Thais to evaluate the relationship between these cell
subsets and IQ. Inclusion of such data would also have
allowed us to control for non-HIV confounders such as
socioeconomic status and caregiver’s education.
Nevertheless, we observed a strong association be-
tween higher B cells and poorer FIQ, VIQ and PIQ.
Long term study of this PREDICT cohort of children
randomized to immediate versus deferred ART initiation
may enable us to further elucidate these relationships,
and identify cellular subsets which could perhaps pre-
dict poor neurodevelopment. This in turn, could help
identify children that would benefit from early ART
and/or close monitoring and intervention to improve
neurodevelopment.
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